AskBorsa

Alexandria Pharmaceuticals

AXPH
Fiscal year starts in July · currency EGP · latest: Q3 2026
Net profit · 2024
217million
71.4% vs 2023
Total assets · 2024
1.24billion
34.5% vs 2023
Shareholders' equity · 2024
795million
20.4% vs 2023
Operating cash flow · 2024
190million
107.6% vs 2023

Key facts

Source: annual statements 2024
  • Alexandria Pharmaceuticals's net profit in 2024 was 217 million EGP, up 71.4% from 126 million EGP in 2023.
  • Total assets at the end of 2024 were 1.24 billion EGP, and shareholders' equity 795 million EGP.
  • Operating cash flow in 2024 was positive at 190 million EGP.
AI summary

Preparing a summary of the latest results…

Annual net profit last 5 years
Net profit
170million
117million
117million
126million
217million
20202021202220232024

Summarised financial statements

Excel · Pro
Swipe the table to see the other years.
Item · EGP20202021202220232024
Income statement
Net profit170 million117 million117 million126 million217 million
Gross profit344 million293 million461 million295 million613 million
Total assets799 million793 million875 million923 million1.24 billion
Total liabilities227 million207 million245 million263 million446 million
Shareholders' equity572 million586 million630 million660 million795 million
Total liabilities and equity799 million793 million875 million923 million1.24 billion
Operating cash flow140 million99.42 million193 million91.34 million190 million
Investing cash flow-60.02 million-114 million-26.6 million-77.84 million-48.33 million
Financing cash flow-78.08 million-100 million-64.52 million-76.94 million-82 million
Net change in cash1.7 million-114 million102 million-63.44 million59.3 million
Sign up free to see the full five years for every period.
Sign up free in seconds
With Google or your email, no password.

Figures in Egyptian pounds from the published statement summaries, after normalising reporting units across periods. The exact figure is in the attached report.

Financial reports (14)